The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
 
Naoki Furuya
No Relationships to Disclose
 
Tatsuro Fukuhara
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Haruhiro Saito
No Relationships to Disclose
 
Kana Watanabe
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Shunichiro Iwasawa
Speakers' Bureau - AstraZeneca Japan; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Yoshio Tsunezuka
No Relationships to Disclose
 
Ou Yamaguchi
Consulting or Advisory Role - AstraZeneca Japan
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical
 
Morihito Okada
Speakers' Bureau - Chugai Pharma; Covidien; Johnson & Johnson; Lilly; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Pfizer (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kouzou Yoshimori
No Relationships to Disclose
 
Ichiro Nakachi
No Relationships to Disclose
 
Akihiko Gemma
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma
 
Koichi Azuma
No Relationships to Disclose
 
Koichi Hagiwara
Honoraria - AstraZeneca Japan; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - LSI Medience Corporation
 
Toshihiro Nukiwa
Consulting or Advisory Role - Asahi Kasei; Nippon Boehringer Ingelheim
 
Satoshi Morita
Honoraria - Chugai Pharma
 
Kunihiko Kobayashi
Consulting or Advisory Role - AstraZeneca Japan
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly; Ono Pharmaceutical
 
Makoto Maemondo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst)